Similar results were obtained with an external validation cohort of patients with lymphoma treated with the CHOP regimen, with a 10-year cumulative incidence of t-MN of 29% in CHIP carriers vs. 0% in patients without CH (p = 0.009) [45]. Here, STUB1 is linked to lymphoma.